# Cabozantinib for Adults With Advanced Soft Tissue Sarcoma

> **NCT01755195** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 55 (actual)

## Conditions studied

- Refractory Soft Tissue Sarcomas

## Interventions

- **DRUG:** Cabozantinib

## Key facts

- **NCT ID:** NCT01755195
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01-15
- **Primary completion:** 2020-09-30
- **Final completion:** 2023-09-11
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2024-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01755195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01755195, "Cabozantinib for Adults With Advanced Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01755195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*